Implementation of Pharmacogenomic Information on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Abstract

Drug-related Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare but severe adverse drug reactions, termed as idiosyncratic reactions; however, predicting their onset remains challenging. Pharmacogenomic information associated with SJS/TEN has accumulated on several drugs in the last 15 years, with clinically useful information now included on drug labels in several countries/regions or guidelines of the Clinical Pharmacogenetics Implementation Consortium (CPIC) for implementation. However, label information might be different among countries. This mini-review summarizes pharmacogenomic information on drug labels of five drugs in six countries and compared descriptions of drug labels and CPIC guidelines. Finally, we discuss future perspectives of this issue. Pharmacogenomic information on drug labels is not well-harmonized across countries/regions, but CPIC guidelines are a scientifically sound goal for future pharmacogenomic implementation.

Stevens-Johnson syndrome: what do we know about it?

“…The Stevens-Johnson Syndrome (SSJ), described in 1922, is characterized by hypersensitivity to the use of some drugs that presents several reactions, from rare to severe, and may lead to death (1). In 1950, the condition was divided into two categories: erythema multiforme minor (Von Hebra) and erythema multiforme major, which became known as Stevens Johnson Syndrome (SSJ) (2).…”